Certified by Founder
Lodge
Matchpoint Therapeutics
start up
United States
- Cambridge, Massachusetts
- 17/10/2022
- Series A
- $100,000,000
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
- Industry Biotechnology Research
- Website https://matchpointtx.com/
- LinkedIn https://www.linkedin.com/company/matchpoint-therapeutics/